Cerity Partners LLC Increases Holdings in Pfizer Inc. $PFE

Cerity Partners LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 83.3% during the 4th quarter, Holdings Channel reports. The institutional investor owned 3,187,455 shares of the biopharmaceutical company’s stock after acquiring an additional 1,448,806 shares during the quarter. Cerity Partners LLC’s holdings in Pfizer were worth $79,368,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in PFE. Brighton Jones LLC raised its position in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares during the last quarter. United Bank grew its holdings in Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after purchasing an additional 6,415 shares during the last quarter. Sei Investments Co. grew its holdings in Pfizer by 31.5% during the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after purchasing an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC grew its holdings in Pfizer by 45.3% during the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after purchasing an additional 31,896 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of PFE stock opened at $25.67 on Wednesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The company has a market capitalization of $146.28 billion, a P/E ratio of 19.59 and a beta of 0.34. The company’s 50-day simple moving average is $26.56 and its two-hundred day simple moving average is $26.31. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same period last year, the firm earned $0.92 earnings per share. The company’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved an expanded indication for HYMPAVZI, broadening use to more hemophilia A/B patients and children, which could increase future sales. Article Title
• Positive Sentiment: Pfizer’s obesity pipeline remains in focus after phase 2b data showed about 16% weight loss, reinforcing optimism that the company may build a meaningful next-generation growth franchise. Article Title
• Neutral Sentiment: BMO Capital kept its Buy rating on Pfizer, adding support for the stock but not changing the core story by itself. Article Title
• Neutral Sentiment: Multiple articles highlighted Pfizer’s obesity strategy and its effort to find new growth after the COVID windfall faded, which is encouraging but still early-stage. Article Title
• Negative Sentiment: Broader commentary on patent cliffs and rising competition in obesity drugs underscores the pressure Pfizer faces to replace lost revenue and prove its pipeline can deliver. Article Title

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on PFE shares. Wolfe Research reiterated an “underperform” rating and set a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. Guggenheim upped their price target on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Bank of America cut their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Finally, Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus price target of $28.82.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.